Table 1.

Patient and Treatment Characteristics

Characteristic	No. of Patients	%
Total patients	79	100
Age, years
< 50	6	9
50-69	47	59
≥ 70	26	32
Sex
Female	33	42
Male	46	58
Stage
I/II	7	9
IIIA	21	27
IIIB	35	44
IV	10	13
Recurrent	6	8
Histology
Adenocarcinoma	24	30
Squamous cell carcinoma	26	33
NSCLC, NOS	22	28
Other NSCLC	7	9
Bin assignment, rNTDmean
Pilot (NA)	5	6
1 (0.00-0.119)	6	7
2 (0.12-0.179)	8	10
3 (0.18-0.239)	27	34
4 (0.24-0.309)	29	37
5 (0.31-0.410)	4	5
Performance status
0	48	61
1	30	38
Not recorded	1	1
Prescribed radiation dose, Gy
57	47	59
63.25	11	14
69.25	3	4
75	12	16
80.5	4	5
85.5	2	3
Chemotherapy
Neoadjuvant	17	21
Adjuvant	33	41
Both	3	4
None	25	32
Other*	1	1

Abbreviations: NA, not applicable; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; rNTD_mean, mean normalized tissue (lung) dose divided by normalized prescription dose.

^*Patient received erlotinib before, during, and after radiation.